Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Products

Set Alert for Products

Generics Explore this Topic

Set Alert for Generics

ATOM Coalition Seeks Partners To Create New Oncology Markets

The ATOM Coalition is seeking partners in the generics and biosimilars industry to help create new markets for cancer medicines in LLMICs.

Cancer Market Access

Waverley Weighs Its Options With High Costs, Thin Margins

Waverley is evaluating options for its generics as it looks likely to throw its all at the company’s lead product candidate in the hopes of luring a development partner or buyer.

Generic Drugs Strategy

Successful Cortrophin Gel Launch Could Drive Growth At ANI For Years To Come

The launch of ANI Pharmaceutical’s Cortrophin gel has reignited interest in the ACTH drug category, and appears set to drive growth at the company for the foreseeable future.

Sales & Earnings Rare Diseases
See All

Biosimilars Explore this Topic

Set Alert for Biosimilars

‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars

With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – tells Generics Bulletin that the US biosimilars market is “doing better, but we still have improvements to make.”

Biosimilars United States

ATOM Coalition Seeks Partners To Create New Oncology Markets

The ATOM Coalition is seeking partners in the generics and biosimilars industry to help create new markets for cancer medicines in LLMICs.

Cancer Market Access

Dr Reddy’s Can Still Go It Alone After Penning Orencia Biosimilar Deal

Targeting a dual biologic for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, Coya Therapeutics has joined forces with abatacept biosimilar developer Dr Reddy’s.

Biosimilars Biologics
See All

Value-Added Medicines Explore this Topic

Set Alert for Value-Added Medicines

Hyloris Lines Up Hectic Year Of Clinical Trials And Major US Launch

Hyloris has an eventful year ahead as it plans to conduct numerous trials for products in its ever-expanding pipeline and launch Maxigesic IV in the US.

Value-Added Medicines Clinical Trials

Fresh Competition Coming For Narcan In US

Further US hybrid and generic rivals to Narcan are in the works, with Amphastar having just received an FDA nod for its naloxone nasal spray in a proprietary device as Amneal files an ANDA for a further generic version.

Approvals United States

Coherus Pulls A Rabbit Out Of The Hat With Inventive Pegfilgrastim Form

Coherus’ year-end financial results included a surprise – a newly approved formulation of pegfilgrastim.

Approvals Biosimilars
See All
UsernamePublicRestriction

Register